1. For all slides in this series, the following notes apply:
Estimated numbers and rates of diagnoses of HIV infection are based on data from 46 states and 5 U.S. dependent areas that have had confidential name-based HIV infection reporting for a sufficient length of time (i.e., implemented in area since at least January 2007 and reported to CDC since at least June 2007) to allow for stabilization of data collection and for adjustment of the data in order to monitor trends.
Estimated numbers and rates of AIDS diagnoses are based on data from the 50 states, the District of Columbia, and 6 U.S. dependent areas. For the first time, the Republic of Palau has been included in numbers and rates of AIDS diagnoses, deaths, and persons living with AIDS.
Rates are not calculated by race/ethnicity for the 6 U.S. dependent areas because the U.S. Census Bureau does not collect information from all U.S. dependent areas.
At the time of development of this slide series, complete 2010 census data were not available from the U.S. Census Bureau. Therefore, all U.S. population estimates and denominators used to calculate rates were based on the official postcensus estimates for 2009.

2. This slide presents the percentage distribution of diagnoses of HIV infection among adults and adolescents diagnosed from 2007 through 2010, by transmission category, for 46 states and 5 U.S. dependent areas with long-term confidential name-based HIV infection reporting.
The percentage of diagnoses of HIV infection among adults and adolescents exposed through male-to-male sexual contact increased from 55% in 2007 to 61% in The percentages of diagnosed HIV infections attributed to injection drug use, male-to-male sexual contact and injection drug use, and heterosexual contact remained relatively stable from
The remaining diagnoses of HIV infection were those attributed to hemophilia or the receipt of blood or blood products, perinatal exposure, and those in persons without an identified risk factor.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Heterosexual contact is with a person known to have, or to be at high risk for, HIV infection.

3. In 2010, among adult and adolescent males diagnosed with HIV infection in the 46 states and 5 U.S. dependent areas with long-term confidential name-based HIV infection reporting, an estimated 77% of infections were attributed to male-to-male sexual contact and 7% were attributed to injection drug use. Approximately 12% of diagnosed infections were attributed to heterosexual contact and 4% attributed to male-to-male sexual contact and injection drug use.
Most (86%) diagnosed HIV infections among adult and adolescent females were attributed to heterosexual contact, and 14% were attributed to injection drug use.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Heterosexual contact is with a person known to have, or to be at high risk for, HIV infection.

4. This slide shows a comparison between male and female injection drug users (IDUs) diagnosed with HIV infection in 2010, by race/ethnicity, in the 46 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January Among male IDUs, an estimated 46% were black/African American, 32% were Hispanic/Latino and 19% were white. In comparison, among female IDUs, 51% were black/African American, 30% were white, and 15% were Hispanic/Latino.
Among both sexes, American Indian/Alaska Native, Asian, Native Hawaiian/other Pacific Islander, and persons reporting multiple races each comprised 2% or less of IDUs.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data on injection drug use among males do not include men with HIV infection attributed to male-to-male sexual contact and injection drug use.
Hispanics/Latinos can be of any race.

5. In 2010, an estimated 4,007 diagnoses of HIV infections among adult and adolescent were attributed to injection drug use (IDU) in the 46 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2007.
Approximately 48% of the diagnosed HIV infections attributed to IDU were among blacks/African Americans and 26% were among Hispanics/Latinos. Most of the remaining cases were among whites (23%). American Indians/Alaska Natives, Asians, and persons of multiple races each accounted for approximately 1% of diagnoses of HIV infection. Native Hawaiians/other Pacific Islanders accounted for less than 1% of diagnoses.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data exclude men with HIV infection attributed to male-to-male sexual contact and injection drug use.
Hispanics/Latinos can be of any race.

6. In 2010, an estimated 2,581 adult and adolescent male injection drug users (IDUs) were diagnosed with HIV infection in the 46 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2007.
Of these male IDUs diagnosed with HIV infections, approximately 47% were among blacks/African Americans, and 32% were among Hispanics/Latinos. Most of the remaining cases were among whites (19%).
Asians and persons of multiple races each accounted for approximately 1% of diagnoses of HIV infection among male IDUs. American Indians/Alaska Natives and Native Hawaiians/other Pacific Islanders each accounted for less than 1% of diagnoses.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data exclude men with HIV infection attributed to male-to-male sexual contact and injection drug use.
Hispanics/Latinos can be of any race.

7. In 2010, an estimated 1,426 adult and adolescent female injection drug users (IDUs) were diagnosed with HIV infection in the 46 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2007.
Of these female IDUs diagnosed with HIV infections, approximately 51% were among blacks/African Americans, and 30% were among whites. Most of the remaining cases were among Hispanics/Latinos (15%).
Persons of multiple races accounted for approximately 2% of diagnoses of HIV infection among female IDUs. American Indians/Alaska Natives and Asians each accounted for approximately 1% of diagnoses, and Native Hawaiians/other Pacific Islanders accounted for less than 1% of diagnoses.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Hispanics/Latinos can be of any race.

8. This slide shows estimated data by IDU-related transmission category and age group, for diagnoses of HIV infection during 2010, from the 46 states and 5 U.S. dependent areas with confidential named-based HIV infection reporting since at least January Two standard transmission categories are collectively referred to as related to injection drug use (IDU-related), and these two categories are mutually exclusive: injection drug use; and male-to-male sexual contact and injection drug use. For this slide, the injection drug use category has been further separated by sex.
Overall, the number of IDU-related diagnoses of HIV infection increased as age increased. The percentage of IDU-related cases among male injection drug users generally increased with increasing age, while the percentage was generally stable among females regardless of age. The percentage of diagnoses among men with HIV infection attributed to male-to-male sexual contract and injection drug use generally decreased with increasing age.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.

9. This slide shows diagnosed HIV infections related to injection drug use by age group and race/ethnicity in the 46 states and 5 U.S. dependent areas with confidential named-based HIV infection reporting since at least January Two standard transmission categories are collectively referred to as related to injection drug use (IDU-related), and these two categories are mutually exclusive: injection drug use; and male-to-male sexual contact and injection drug use.
Of the estimated 5,481 IDU-related diagnosed HIV infections in 2010, 43% were among blacks/African Americans, 29% were among whites, and 25% were among Hispanic/Latinos. Overall, the number of IDU-related diagnoses of HIV infection increased as age increased. The percentage of IDU-related cases among blacks/African Americans decreased with increasing age until the 25–34 age group, for which percentages then increased with increasing age. The percentage of IDU-related cases among Hispanics/Latinos and among whites increased with increasing age until the 25–34 age group, for which percentages then decreased with increasing age. Persons of multiple races accounted for approximately 2% of diagnosis of HIV infection (all age groups) accounted for approximately 2% of IDU-related cases. American Indians/Alaska Natives (all age groups) and Asians (all age groups) each accounted for approximately 1% of IDU-related cases. Native Hawaiians/Other Pacific Islanders (all age groups) accounted for less than 1% of IDU-related cases.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.

10. During 2009, an estimated 5,632 deaths occurred among adult and adolescent injection drug users (IDUs) with a diagnosis of HIV infection in the 46 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January Blacks/African Americans accounted for the highest percentage of deaths among IDUs (53%) followed by Hispanics/Latinos (23%) and whites (20%). Persons of multiple races accounted for approximately 3% of deaths among IDUs, American Indians/Alaska Natives accounted for approximately 1% of deaths among IDUs, and Asians accounted for less than 1% of deaths among IDUs. There were no IDU-related deaths among Native Hawaiians/other Pacific Islanders.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data exclude men with HIV infection attributed to male-to-male sexual contact and injection drug use.
The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old Office of Management and Budget race/ethnicity classification system).
Hispanics/Latinos can be of any race.

11. At the end of 2009, an estimated 133,918 adult and adolescent injection drug users (IDUs) were living with a diagnosis of HIV infection in the 46 states and 5 U.S. dependent areas with confidential name-based HIV infection reporting since at least January 2007.
Approximately 50% of IDUs living with a diagnosis of HIV infection at the end of 2009 were black/African American, 27% were Hispanic/Latino, and 21% were white. Persons of multiple races accounted for approximately 2% of IDUs living with a diagnosis of HIV infection. American Indians/Alaska Natives, Asians, and Native Hawaiians/other Pacific Islanders accounted for less than 1% each of IDUs living with a diagnosis of HIV infection.
The following 46 states have had laws or regulations requiring confidential name-based HIV infection reporting since at least January 2007 (and reporting to CDC since at least June 2007): Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. The 5 U.S. dependent areas include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico and the U.S. Virgin Islands.
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data exclude men with HIV infection attributed to male-to-male sexual contact and injection drug use.
The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old Office of Management and Budget race/ethnicity classification system).
Hispanics/Latinos can be of any race.

12. The estimated number of AIDS diagnoses among injection drug users (IDUs) in the United States and 6 U.S. dependent areas increased during 1985–1993, and decreased thereafter. During 1993, there were an estimated 24,385 AIDS diagnoses among IDUs. In 2010, there were an estimated 4,696 AIDS diagnoses among IDUs. Among men who have sex with men who also inject drugs, 6,410 were diagnosed with AIDS in After 1992, a decreasing trend occurred in this group. In 2010, an estimated 1,474 men with HIV infection attributed to male-to-male sexual contact and injection drug received an AIDS diagnosis.
All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Heterosexual contact is with a person known to have or to be at high risk for HIV infection.

13. In 2010, the estimated number of AIDS diagnoses among male adults and adolescents (25,186) in the United States and 6 U.S. dependent areas was nearly 3 times the number among females (8,422). Among males, 12% of AIDS diagnoses were attributed to injection drug use, and 6% to male-to-male sexual contact and injection drug use. Among females, 21% of AIDS diagnoses were attributed to injection drug use.
All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Heterosexual contact is with a person known to have or to be at high risk for HIV infection.

14. During 1985–2010, the percentage of AIDS diagnoses attributed to injection drug use (IDU) ranged from a minimum of 14% to a maximum of 31% in the United States and 6 U.S. dependent areas: 20% in 1985 with a gradual increase through 1993; 31% in 1993; gradual decrease from 1994-onward; and 14% in The greatest number of AIDS diagnoses among IDUs was 24,385 in 1993.
All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data exclude men with HIV infection attributed to male-to-male sexual contact and injection drug use.

15. This graph shows the racial/ethnic trends in estimated AIDS diagnoses in the United States and 6 U.S. dependent areas during 1985–2010 among adult and adolescent injection drug users (IDUs). Rates by race and ethnicity, important for understanding the impact of HIV on racial/ethnic groups, are not presented due to the difficulty in obtaining the total number of IDUs in each race/ethnicity category.
Noteworthy is the decline from 1993 through 2010 in AIDS diagnoses among black/African American IDUs. Despite this decline, the largest number of AIDS diagnoses among IDUs each year was in blacks/African Americans. The second largest number of AIDS diagnoses among IDUs was in Hispanics/Latinos, followed by whites. Very few AIDS diagnoses among IDUs were in American Indians/Alaska Natives, Asians, Native Hawaiians/other Pacific Islanders, and persons of multiple races.
All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data exclude men with HIV infection attributed to male-to-male sexual contact and injection drug use.
The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old Office of Management and Budget race/ethnicity classification system).
Hispanics/Latinos can be of any race.

16. In 2010, an estimated 2,906 AIDS diagnoses were among adult and adolescent male injection drug users (IDUs) in the United States and 6 U.S. dependent areas. Of AIDS diagnoses among IDUs, an estimated 1,461 (50%) were in black/African American males. The number of AIDS diagnoses in black/African American male IDUs was nearly twice the number of AIDS diagnoses in Hispanic/Latino male IDUs (864), and nearly three times as high as the number in white male IDUs (492).
All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data exclude men with HIV infection attributed to male-to-male sexual contact and injection drug use.
The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old Office of Management and Budget race/ethnicity classification system).
Hispanics/Latinos can be of any race.

17. In 2010, an estimated 1,790 AIDS diagnoses were among adult and adolescent female injection drug users (IDUs) in the United States and 6 U.S. dependent areas. Of AIDS diagnoses among female IDUs, an estimated 989 (55%) were in black/African American females. The number of AIDS diagnoses in black/African American female IDUs was more than three times as high as the number in Hispanic/Latino female IDUs (299) and more than two times as high as the number of AIDS diagnoses in white female IDUs (430).
All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old Office of Management and Budget race/ethnicity classification system).
Hispanics/Latinos can be of any race.

18. In 2010, an estimated 4,696 AIDS diagnoses were among injection drug users (IDUs) residing in the United States (includes 50 states and District of Columbia) and 6 U.S. dependent areas. Of these, the greatest number of AIDS diagnoses was among IDUs in the South (1,793), followed by IDUs in the Northeast (1,725). In all regions except the West, the largest percentage of AIDS diagnoses among IDUs was in blacks/African Americans. In the Northeast, blacks/African Americans accounted for 812 (47%), and Hispanics/Latinos accounted for 594 (34%) of AIDS diagnoses among IDUs. Inter-region comparisons of estimated numbers of AIDS diagnoses should be made cautiously because the four regions and the U.S. dependent areas vary by number of jurisdictions and by population size. In the South, blacks/African Americans accounted for 1,215 (68%) of AIDS diagnoses among IDUs and whites accounted for 342 (19%) of AIDS diagnoses among IDUs.
Regions of residence are defined as follows:
Northeast—Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont Midwest—Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin South—Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia West—Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming
6 U.S. dependent areas—American Samoa, Guam, the Northern Mariana Islands, Puerto Rico Republic of Palau and the U.S. Virgin Islands
All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data exclude men with HIV infection attributed to male-to-male sexual contact and injection drug use.
The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old Office of Management and Budget race/ethnicity classification system).
Hispanics/Latinos can be of any race.

19. At the end of 2009, an estimated 97,754 adult and adolescent injection drug users (IDUs) were living with an AIDS diagnosis in the United States and 6 U.S. dependent areas.
Approximately 52% of IDUs living with an AIDS diagnosis at the end of 2009 were black/African American, 26% were Hispanic/Latino, and 19% were white. Persons of multiple races accounted for approximately 2% of IDUs living with an AIDS diagnosis. American Indians/Alaska Natives, Asians, and Native Hawaiians/other Pacific Islanders accounted for less than 1% each of IDUs living with an AIDS diagnosis.
All displayed data are estimates. Estimated numbers resulted from statistical adjustment that accounted for reporting delays and missing risk-factor information, but not for incomplete reporting.
Data exclude men with HIV infection attributed to male-to-male sexual contact and injection drug use.
The Asian category includes Asian/Pacific Islander legacy cases (cases that were diagnosed and reported under the old Office of Management and Budget race/ethnicity classification system).
Hispanics/Latinos can be of any race.